

Sub F1 → --25. An immunogenic polypeptide, comprising a self IgE portion and a non-self IgE portion, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, wherein said self IgE portion comprises at least a portion of a CH3 domain of IgE, and wherein said immunogenic polypeptide lacks a CH1 domain of IgE.

C3 26. The immunogenic polypeptide of claim 25, wherein said mammal is a human.

Sub F2 → 27. The immunogenic polypeptide of claim 26, wherein said non-self IgE portion comprises an IgE sequence present in a non-placental mammal.

Sub G4 → 28. The immunogenic polypeptide of claim 27, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

29. The immunogenic polypeptide of claim 25, wherein said polypeptide is capable of dimerizing to form a soluble immunogenic dimer effective to induce said anti-self IgE response in said mammal.

30. The immunogenic polypeptide of claim 25, wherein said non-self IgE portion comprises a first region and a second region, said self IgE portion being located between said first and second regions of said non-self IgE portion.

Sub F3 → 31. The immunogenic polypeptide of claim 30, wherein said first region comprises at least a portion of an IgE CH2 domain.

32. The immunogenic polypeptide of claim 30, wherein said second region comprises at least a portion of an IgE CH4 domain.

33. An immunogenic polypeptide, comprising a self IgE portion and a non-self IgE portion, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a

mammal, and wherein said self IgE portion consists essentially of an N-terminal portion of a CH3 domain of IgE.

34. The immunogenic polypeptide of claim 33, wherein said mammal is a human.

C?
sub
Fig 4
~~35. The immunogenic polypeptide of claim 34, wherein said non-self IgE portion comprises an IgE sequence present in a non-placental mammal.~~

sub
G6
~~36. The immunogenic polypeptide of claim 35, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.~~

37. The immunogenic polypeptide of claim 33, wherein said polypeptide is capable of dimerizing to form a soluble immunogenic dimer effective to induce said anti-self IgE response in said mammal.

sub
Fig 5
~~38. The immunogenic polypeptide of claim 33, wherein said non-self IgE portion comprises a first region and a second region, said self IgE portion being located between said first and second regions of said non-self IgE portion.~~

39. The immunogenic polypeptide of claim 38, wherein said first region comprises at least a portion of an IgE CH2 domain.

40. The immunogenic polypeptide of claim 38, wherein said second region comprises at least a portion of an IgE CH4 domain.

41. An immunogenic polypeptide, comprising a self IgE portion and a non-self IgE portion, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, and wherein said non-self IgE portion comprises an IgE sequence present in a non-placental mammal.

42. The immunogenic polypeptide of claim 41, wherein said mammal is a human.
43. The immunogenic polypeptide of claim 41, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.
44. The immunogenic polypeptide of claim 41, wherein said polypeptide is capable of dimerizing to form a soluble immunogenic dimer effective to induce said anti-self IgE response in said mammal.
45. The immunogenic polypeptide of claim 41, wherein said non-self IgE portion comprises a first region and a second region, said self IgE portion being located between said first and second regions of said non-self IgE portion.
46. The immunogenic polypeptide of claim 45, wherein said first region comprises at least a portion of an IgE CH2 domain.
47. The immunogenic polypeptide of claim 45, wherein said second region comprises at least a portion of an IgE CH4 domain.
48. A polypeptide, comprising a self IgE portion and a non-self IgE portion, wherein said polypeptide lacks light chain Ig sequences and is effective to induce an anti-self IgE response in a mammal, wherein said self IgE portion comprises at least a portion of a CH3 domain of IgE.
49. The polypeptide of claim 48, wherein said mammal is a human.
50. The polypeptide of claim 49, wherein said non-self IgE portion comprises an IgE sequence present in a non-placental mammal.
51. The polypeptide of claim 50, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Page : 5

Attorney's Docket No.: 10223-006001

52. The polypeptide of claim 48, wherein said non-self IgE portion comprises a first region and a second region, said self IgE portion being located between said first and second regions of said non-self IgE portion.

53. The polypeptide of claim 52, wherein said first region comprises at least a portion of an IgE CH2 domain.

54. The polypeptide of claim 52, wherein said second region comprises at least a portion of an IgE CH4 domain.--
